Research Topics
| Tamara PringsheimSummaryAffiliation: University of Calgary Country: Canada Publications
|
Detail Information
Publications
Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: a systematic reviewTamara Pringsheim
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
Can J Psychiatry 57:722-7. 2012..Increases are mainly attributable to treatment of disruptive behaviour disorders (DBDs). Our objective was to review the evidence regarding the efficacy of SGAs for DBDs in youth...
Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapyTamara Pringsheim
Department of Clinical Neurosciences and Pediatrics, University of Calgary, Calgary, Alberta
Can J Psychiatry 57:133-43. 2012..However, when tics are more distressing and interfering, the need for tic suppression to improve quality of life is stronger, and patients and clinicians may be more willing to accept the risks of pharmacotherapy...
The incidence and prevalence of Huntington's disease: a systematic review and meta-analysisTamara Pringsheim
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
Mov Disord 27:1083-91. 2012..HD is a devastating neurodegenerative disorder with a higher prevalence in Europe, North America, and Australia than in Asia. The difference in prevalence of this genetic disorder can be largely explained by huntingtin gene haplotypes...
The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009Tamara Pringsheim
Department of Clinical Neurosciences and Pediatrics, University of Calgary, Calgary, Canada
J Child Adolesc Psychopharmacol 21:537-43. 2011..To describe the frequency and trends of use of antipsychotics in Canadian children and adolescents from 2005 to 2009...
The pharmacoepidemiology of antipsychotics for adults with schizophrenia in Canada, 2005 to 2009Tamara Pringsheim
Department of Clinical Neurosciences, University of Calgary, Alberta
Can J Psychiatry 56:630-4. 2011..To describe the frequency and trends in the use of antipsychotics for adults with schizophrenia in Canada from 2005 to 2009...
Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youthTamara Pringsheim
The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children CAMESA Guideline Project
J Can Acad Child Adolesc Psychiatry 20:218-33. 2011..These medications have the potential to cause major metabolic and neurological complications with chronic use...
Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trialsTamara Pringsheim
University of Calgary, Calgary, AB, Canada
Drug Saf 34:651-68. 2011..Given the demonstrated metabolic and neurological adverse effects seen in adult patients on these medications, detailed evaluation of the risk for these adverse effects in children is appropriate...
Complications of antipsychotic therapy in children with tourette syndromeTamara Pringsheim
Department of Clinical Neurosciences and Pediatrics, University of Calgary, Calgary, Alberta, Canada
Pediatr Neurol 43:17-20. 2010..Neurologic complications are uncommon, which is likely attributable to the primary use of atypical antipsychotics in this setting...
Prenatal and perinatal morbidity in children with Tourette syndrome and attention-deficit hyperactivity disorderTamara Pringsheim
Department of Clinical Neurosciences and Pediatrics, University of Calgary, Calgary, Alberta, Canada
J Dev Behav Pediatr 30:115-21. 2009..Low birth weight is a known risk factor for ADHD. The objective of the study was to assess the association between pre- and perinatal morbidity and the comorbid diagnosis of ADHD in children with TS...
Canadian Headache Society guideline for migraine prophylaxisTamara Pringsheim
University of Calgary and the Hotchkiss Brain Institute, Calgary, AB, Canada
Can J Neurol Sci 39:S1-59. 2012..This guideline is focused on patients with episodic migraine (headache on ≤ 14 days a month)...
